Understanding Thrombotic Risk in ET and PV

September 14, 2018
Laura Michaelis, MD

Laura Michaelis, MD, associate professor of medicine, Medical College of Wisconsin, discusses thrombotic risk for patients with essential thrombocythemia and polycythemia vera.

Laura Michaelis, MD, associate professor of medicine, Medical College of Wisconsin, discusses thrombotic risk for patients with essential thrombocythemia (ET) and polycythemia vera (PV).

There are certain early molecular driver mutations that occur in myeloproliferative neoplasms that can predict thrombotic risk in patients. The risk for a patient with any given driver mutation differs between ET, PV, and myelofibrosis. Michaelis says that one of the early questions since theJAK2mutation was described is, why do some people act one way, while others act another?

One answer seems to be that a patient’s thrombotic risk is based on the presence of aJAK2mutation. In light of the discovery ofJAK2,treatment for ET is changing, reflecting the entrance into the genomic era, according to Michaelis. Decision-making for patients is different now compared to 3 years ago based on this information. Importantly, this information means that patients with ET who do not have aJAK2